ResMed (RMD) Competitors

ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Does the media favor RMD or MEDP?

In the previous week, ResMed had 22 more articles in the media than Medpace. MarketBeat recorded 32 mentions for ResMed and 10 mentions for Medpace. Medpace's average media sentiment score of 1.52 beat ResMed's score of 1.41 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	27 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, RMD or MEDP?

ResMed has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Which has higher earnings & valuation, RMD or MEDP?

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	8.10	$1.40B	$9.51	29.95
Medpace	$2.23B	5.76	$404.39M	$13.45	34.04

Do institutionals & insiders hold more shares of RMD or MEDP?

55.0% of ResMed shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Do analysts recommend RMD or MEDP?

ResMed currently has a consensus price target of $274.83, suggesting a potential downside of 3.51%. Medpace has a consensus price target of $406.60, suggesting a potential downside of 11.19%. Given ResMed's stronger consensus rating and higher probable upside, analysts plainly believe ResMed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.81
Medpace	3 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

Is RMD or MEDP more profitable?

ResMed has a net margin of 27.22% compared to Medpace's net margin of 18.74%. Medpace's return on equity of 67.66% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.22%	25.62%	18.69%
Medpace	18.74%	67.66%	21.86%

Summary

ResMed beats Medpace on 9 of the 17 factors compared between the two stocks.